Azurity Pharmaceuticals INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersWilmington, MA
US patents40
SAM.gov UEILR2EABGHXSX5
CAGE code6X2Y0
Incorporated inDE
LEI254900JTI5G4OG3R9S27
- therapeutic areas
- medicines
- 10 dosage forms
Named on the company’s own website, read JUL 29, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
40 US patents granted 2021–2025, 40 of them in the five years to SEP 2025.
Pharmaceuticals 39Handling 1
- Stable pharmaceutical compositions of bendamustineUS 12,419,867 · granted SEP 23, 2025
- Pharmaceutical compositions of nilotinibUS 12,403,140 · granted SEP 2, 2025
- Amlodipine formulationsUS 12,383,498 · granted AUG 12, 2025
- Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolateUS 12,383,491 · granted AUG 12, 2025
- Liquid nimodipine compositionsUS 12,377,081 · granted AUG 5, 2025
Newest 5 shown · Granted to Azurity Pharmaceuticals, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plants
2 FACILITIES| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Azurity Pharmaceuticals INC | Wilmington | MA | — | UNVERIFIED |
| Azurity Pharmaceuticals INC | Wilmington | MA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.